Skip to content

Janux Therapeutics JANX Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net

Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net at other companies

Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$2.6M-27.8%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$28K-106%
Sana Biotechnology logo
Sana BiotechnologySANA
$1.5M+268%
Netscout Systems logo
Netscout SystemsNTCT
$2.37M-7.3%
ArcBest logo
ArcBestARCB
$34K-99.7%
SHO
Sunstone Hotel InvestorsSHO
-$217K-53.9%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$889.15M-36.3%
Enterprise value$858.89M-36.2%
P/S64.8×-84.8×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept janx:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net?
Janux Therapeutics (JANX) reported increase decrease in operating lease right of use assets and liabilities net of $36K in Q1 2026.
How has Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net changed year-over-year?
Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net increased by 620.0% year-over-year, from $5K to $36K.
What is the long-term trend for Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net?
Over 2 years (2021 to 2023), Janux Therapeutics's increase decrease in operating lease right of use assets and liabilities net has grown at a 767.9% compound annual growth rate (CAGR), from -$9K to -$678K.
What does increase decrease in operating lease right of use assets and liabilities net mean?
This metric captures the net change in the balance sheet values of operating lease right-of-use assets and their corresponding lease liabilities. It reflects the non-cash impact of lease accounting standards on operating cash flow, specifically accounting for the amortization of the asset and the reduction of the lease liability. Monitoring this helps investors understand the company's commitment to long-term lease obligations and their impact on liquidity.